专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160000972A1 COMPOSITIONS AND METHODS FOR TREATING THE VERTEBRAL COLUMN 审中-公开
标题翻译：用于治疗VERTEBRAL COLUMN的组合物和方法
公开(公告)号：US20160000972A1
公开(公告)日：2016-01-07
申请号：US14853901
申请日：2015-09-14
申请人： BioMimetic Therapeutics, LLC
发明人： Charles E. Hart , Samuel E. Lynch , Conan S. Young , Dan Perrien
IPC分类号： A61L27/48 , A61L27/54 , A61L27/42
CPC分类号： A61L27/48 , A61K9/0024 , A61K38/1858 , A61K49/0433 , A61K49/0452 , A61L27/227 , A61L27/425 , A61L27/54 , A61L2300/202 , A61L2300/252 , A61L2300/414 , A61L2300/44 , A61L2300/45 , A61L2400/06 , A61L2430/38
摘要： The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention.
摘要翻译：本发明涉及可用于治疗包括椎体在内的脊柱结构的组合物和方法。在一个实施方案中，一种用于促进椎体中骨形成的方法，包括提供包含PDGF溶液和生物相容性基质的组合物，并将该组合物施用于至少一个椎体。根据一些实施方案，在椎体中促进骨形成可以增加骨量，质量和/或密度，导致用本发明的组合物治疗的椎体的机械强度增加。

2. 发明授权

US09161967B2 Compositions and methods for treating the vertebral column 有权
标题翻译：用于治疗脊柱的组合物和方法
公开(公告)号：US09161967B2
公开(公告)日：2015-10-20
申请号：US12631731
申请日：2009-12-04
申请人： Charles E. Hart , Samuel E. Lynch , Conan S. Young , Dan Perrien
发明人： Charles E. Hart , Samuel E. Lynch , Conan S. Young , Dan Perrien
IPC分类号： A61K38/18 , A61K38/17 , A61K9/00 , A61K49/04 , A61L27/22 , A61L27/42 , A61L27/54
CPC分类号： A61L27/48 , A61K9/0024 , A61K38/1858 , A61K49/0433 , A61K49/0452 , A61L27/227 , A61L27/425 , A61L27/54 , A61L2300/202 , A61L2300/252 , A61L2300/414 , A61L2300/44 , A61L2300/45 , A61L2400/06 , A61L2430/38
摘要： The present invention relates to compositions and methods useful for treating structures of the vertebral column, including vertebral bodies. In one embodiment, a method for promoting bone formation in a vertebral body comprising providing a composition comprising a PDGF solution and a biocompatible matrix and applying the composition to at least one vertebral body. Promoting bone formation in a vertebral body, according to some embodiments, can increase bone volume, mass, and/or density leading to an increase in mechanical strength of the vertebral body treated with a composition of the present invention.
摘要翻译：本发明涉及可用于治疗包括椎体在内的脊柱结构的组合物和方法。在一个实施方案中，一种用于促进椎体中骨形成的方法，包括提供包含PDGF溶液和生物相容性基质的组合物，并将该组合物施用于至少一个椎体。根据一些实施方案，在椎体中促进骨形成可以增加骨量，质量和/或密度，导致用本发明的组合物治疗的椎体的机械强度增加。

3. 发明申请

US20150190533A1 X-RAY IMAGING CONTRAST MEDIA WITH LOW IODINE CONCENTRATION AND X-RAY IMAGING PROCESS 有权
标题翻译：具有低碘浓度和X射线成像过程的X射线成像对比介质
公开(公告)号：US20150190533A1
公开(公告)日：2015-07-09
申请号：US14371350
申请日：2013-01-10
申请人： GE HEALTHCARE AS
发明人： Ben Newton , Mikkel Thaning , Dirk-Jan in't Veld , Karina Langseth , Paul Michael Evans
IPC分类号： A61K49/04 , A61B6/03 , A61B6/00
CPC分类号： A61K49/0438 , A61B6/032 , A61B6/481 , A61K49/0433
摘要： The present invention relates to X-ray examinations and to the improvement of patient safety during such. More specifically the invention relates to X-ray diagnostic compositions having low concentrations of iodine and an optimized amount of electrolytes. The invention further relates to methods of X-ray examinations wherein a body is administered with an X-ray diagnostic composition comprising a low concentration of iodine and irradiated with a radiation dose.
摘要翻译：本发明涉及X射线检查和改善患者安全性。更具体地，本发明涉及具有低浓度碘和优化电解质量的X射线诊断组合物。本发明还涉及X射线检查的方法，其中向身体施用包含低浓度碘并用辐射剂量照射的X射线诊断组合物。

4. 发明申请

US20140227193A1 Preparation for Restenosis Prevention 审中-公开
公开(公告)号：US20140227193A1
公开(公告)日：2014-08-14
申请号：US14255359
申请日：2014-04-17
申请人： Bayer Intellectual Property Gmbh
发明人： Ulrich SPECK , Bruno SCHELLER
IPC分类号： A61L29/08 , A61K49/04 , A61L29/18 , A61L29/16
CPC分类号： A61L29/08 , A61K9/0019 , A61K9/5094 , A61K31/095 , A61K31/165 , A61K31/337 , A61K45/06 , A61K49/0433 , A61K49/0438 , A61K49/0447 , A61K49/0452 , A61K49/105 , A61K49/106 , A61K49/18 , A61L29/16 , A61L29/18 , A61L31/16 , A61L2300/416 , A61K2300/00
摘要： The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.

5. 发明授权

US08420857B2 Removal of silica from water soluble compounds by nanofiltration and reverse phase chromatography 有权
标题翻译：通过纳滤和反相色谱从水溶性化合物中除去二氧化硅
公开(公告)号：US08420857B2
公开(公告)日：2013-04-16
申请号：US12675130
申请日：2008-08-21
申请人： Allan R. Bailey , David H. White , Derick L. Kaspar , Robert E. Vandas , Michael J. Gentilcore , Hung V. Nguyen , Anna K. Fukunaga
发明人： Allan R. Bailey , David H. White , Derick L. Kaspar , Robert E. Vandas , Michael J. Gentilcore , Hung V. Nguyen , Anna K. Fukunaga
IPC分类号： C07C231/24
CPC分类号： B01D61/027 , A61K49/0433 , A61K49/103 , A61K49/106 , B01D15/325 , B01D2315/16
摘要： A process for separating soluble silica species such as monomeric silicic acid (or monosilicic acid) and low molecular weight soluble polymeric silica from impure water soluble compounds by membrane nanofiltration is provided. A process for separating soluble silica species and colloidal silica from impure water soluble compounds by reverse phase liquid chromatography is also provided.
摘要翻译：提供了通过膜纳滤法从不纯的水溶性化合物中分离可溶性二氧化硅物质例如单体硅酸（或单硅酸）和低分子量可溶性聚合二氧化硅的方法。还提供了通过反相液相色谱从可溶性水溶性化合物中分离可溶性二氧化硅物质和胶体二氧化硅的方法。

6. 发明授权

US08389043B2 Preparation for restenosis prevention 有权
公开(公告)号：US08389043B2
公开(公告)日：2013-03-05
申请号：US12835420
申请日：2010-07-13
申请人： Ulrich Speck , Bruno Scheller
发明人： Ulrich Speck , Bruno Scheller
IPC分类号： B05D3/02 , A61M31/00 , A61M25/10
CPC分类号： A61L29/08 , A61K9/0019 , A61K9/5094 , A61K31/095 , A61K31/165 , A61K31/337 , A61K45/06 , A61K49/0433 , A61K49/0438 , A61K49/0447 , A61K49/0452 , A61K49/105 , A61K49/106 , A61K49/18 , A61L29/16 , A61L29/18 , A61L31/16 , A61L2300/416 , A61K2300/00
摘要： The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.

7. 发明授权

US08323619B2 Contrast agents 失效
标题翻译：对比剂
公开(公告)号：US08323619B2
公开(公告)日：2012-12-04
申请号：US12739989
申请日：2008-11-06
申请人： Veronique Morisson-Iveson , Duncan George Wynn
发明人： Veronique Morisson-Iveson , Duncan George Wynn
IPC分类号： A61K49/04
CPC分类号： C07C237/46 , A61K49/0433
摘要： Compounds of formula (I) RA—CO—N(R2)—(CR12)n—N(R5)—RB and salts or optical active isomers thereof, wherein each R1 independently are the same or different and denotes a hydrogen atom, a hydroxyl group, a C1 to C4 straight of branched alkyl group or a C1 to C4 straight of branched oxyalkyl group; R2 denotes a hydrogen atom or a C1 to C4 straight of branched alkyl group; R5 independently are the same or different and denotes a acyl moiety; RA and RB independently are the same or different and denote a triiodinated phenyl group, preferably a 2,4,6-triiodinated phenyl group further substituted by two groups R3 in the 3 and 5 positions wherein each R3 are the same or different and denote a hydrogen atom or a non-ionic hydrophilic moiety, provided that at least one R3 group in the compound of formula (I) is a hydrophilic moiety; and n denotes a positive integer of 1 to 6. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.
摘要翻译：式（I）化合物RA-CO-N（R2） - （CR12）n-N（R5）-RB及其盐或光学活性异构体，其中每个R 1各自独立地相同或不同，表示氢原子，羟基，支链烷基的C1〜C4直链或支链烷氧基的C1〜C4直链; R2表示氢原子或支链烷基的C1〜C4直链; R5独立地相同或不同，表示酰基部分; RA和RB独立地相同或不同，表示三碘代苯基，优选2,4,6-三碘代苯基，其进一步被3和5位的R3基团取代，其中每个R 3相同或不同，表示氢原子或非离子亲水部分，条件是式（I）化合物中的至少一个R 3基团是亲水部分; 并且n表示1至6的正整数。本发明还涉及这种诊断组合物作为造影剂在诊断成像中，特别是在X射线成像中的用途，以及含有这些化合物的造影剂。

8. 发明授权

US07863047B2 Intracorporeal medicaments for photodynamic treatment of disease 有权
标题翻译：用于光动力治疗疾病的体内药物
公开(公告)号：US07863047B2
公开(公告)日：2011-01-04
申请号：US12150330
申请日：2008-04-25
申请人： H. Craig Dees , Timothy C. Scott , Eric A. Wachter , Walter G. Fisher , John Smolik
发明人： H. Craig Dees , Timothy C. Scott , Eric A. Wachter , Walter G. Fisher , John Smolik
IPC分类号： A61K51/00 , A61K49/00 , A61M36/14 , G01N23/00
CPC分类号： A61K31/352 , A61B2017/00057 , A61B2017/22062 , A61B2017/22087 , A61F7/00 , A61K9/0019 , A61K41/0038 , A61K41/0057 , A61K41/0071 , A61K41/008 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/6803 , A61K49/0041 , A61K49/0433 , A61N5/0601 , A61N5/062 , C07D311/82 , Y02A50/473 , Y10T436/153333 , Y10T436/19 , Y10T436/193333
摘要： New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.
摘要翻译：描述了新的体内光动力学药物和用于治疗人或动物组织中的这种光动力药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤代呫吨衍生物。在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道和相关器官，循环系统内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。在另一个优选的实施方案中，这些药物以包括液体，半固体，固体或气溶胶递送载体的各种制剂生产。

9. 发明申请

US20100322868A1 CONTRAST AGENTS 有权
标题翻译：对比剂
公开(公告)号：US20100322868A1
公开(公告)日：2010-12-23
申请号：US12665792
申请日：2008-07-04
申请人： Mikkel Thaning
发明人： Mikkel Thaning
IPC分类号： A61K49/04 , C07C237/30
CPC分类号： C07C237/46 , A61K49/0433 , A61K49/0438 , A61K49/0452
摘要： The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R—N(CHO)—X—N(R3)—R wherein X denoted an optionally substituted alkylene group, R3 denotes a hydrogen atom or an acyl function and each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.
摘要翻译：本发明涉及一类化合物和含有这些化合物的诊断组合物，其中化合物是含碘化合物。更具体地说，含碘化合物是含有通式R-N（CHO）-X-N（R3）-R的两个连接的碘化苯基的化合物，其中X表示任选取代的亚烷基，R 3表示氢原子或酰基官能团，每个R表示进一步被亲水部分取代的三碘化苯基残基。本发明还涉及这种诊断组合物作为造影剂在诊断成像中，特别是在X射线成像中的用途，以及含有这些化合物的造影剂。

10. 发明申请

US20080207746A1 Intracorporeal medicaments for photodynamic treatment of disease 有权
公开(公告)号：US20080207746A1
公开(公告)日：2008-08-28
申请号：US12150330
申请日：2008-04-25
申请人： H. Craig Dees , Timothy C. Scott , Eric A. Wachter , Walter G. Fisher , John Smolik
发明人： H. Craig Dees , Timothy C. Scott , Eric A. Wachter , Walter G. Fisher , John Smolik
IPC分类号： A61K31/352 , A61P1/00 , A61P11/00 , A61P13/00 , A61P15/00 , A61P9/00 , A61P17/00 , A61P5/00 , A61P31/00 , A61P41/00
CPC分类号： A61K31/352 , A61B2017/00057 , A61B2017/22062 , A61B2017/22087 , A61F7/00 , A61K9/0019 , A61K41/0038 , A61K41/0057 , A61K41/0071 , A61K41/008 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/6803 , A61K49/0041 , A61K49/0433 , A61N5/0601 , A61N5/062 , C07D311/82 , Y02A50/473 , Y10T436/153333 , Y10T436/19 , Y10T436/193333
摘要： New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式